August 11, 2016
User Base for Novartis’ Cosentyx in Psoriatic Arthritis Significantly Expands as Rheumatologists Report High Satisfaction
At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase from the 24% who reported use at one month post-launch, according to a recent report from Spherix Global Insights.
August 11, 2016 – Cambridge, Massachusetts. US rheumatologists are increasingly adopting Novartis’ IL-17 inhibitor, Cosentyx, into their treatment algorithm for psoriatic arthritis (PsA). Cosentyx users report high levels of satisfaction and excitement about the results their PsA patients are achieving with the latest biologic, with over one-quarter of current users citing that they are extremely satisfied with the agent. Furthermore, half of current non-users anticipate initiating trial of Cosentyx within the next three months.
With Cosentyx prescriptions in PsA on the rise, over one-third of rheumatologists believe that Janssen’s Stelara is the most likely to be replaced. Additionally, one-third of rheumatologists also report that Cosentyx has a significant efficacy advantage over Stelara.
With respect to Celgene’s Otezla, rheumatologists believe Cosentyx has a significant advantage over Otezla regarding efficacy in PsA. Indeed, rheumatologists report lower overall satisfaction with the PDE4 inhibitor than with the biologics available in PsA.
Cosentyx appears to be paving the PsA highway for IL-17 inhibitors, much like it paved the way for early adoption of Eli Lilly’s Taltz (ixekizumab) in Psoriasis. Indeed, the vast majority of surveyed rheumatologists foresee a role for Taltz, as well as for Valeant and AstraZeneca’s Siliq (brodalumab) in the future treatment of PsA. Furthermore, the majority of rheumatologists agree that the addition of IL-17 inhibitors as treatment options will greatly improve their ability to efficiently treat PsA.
RealTime Dynamix™: Psoriatic Arthritis, is an independent report issued on a quarterly basis that provides highly granular brand insights on the PsA market. The Q2 report highlighted here provides insight from 100 US rheumatologists.
To view media coverage of this release, click here.
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
For more information contact:
Lynn Price, Immunology Franchise Head